Evaluation Mitigating Cardiovascular Disease Risk Factors Evaluation HMP Education would appreciate your feedback on the quality and impact of this activity.Please answer the following questions, some of which include a 5-point Likert scale (5 = strongly agree/excellent/great deal; 1 = strongly disagree/poor/very little). To what extent are you able to better achieve each of the following learning objectives? Describe the prevalence, burden, and risk factors associated with CVD 5 4 3 2 1 Assess the safety and efficacy of available strategies to mitigate CVD risk 5 4 3 2 1 Evaluate the most recent clinical data on omega-3 fatty acids, including their formulations, mechanisms of action, biological effects, and clinical implications in CVD risk 5 4 3 2 1 Implement recent data, newer therapeutic strategies, and guideline-directed care in clinical practice to minimize CVD risk and improve patient outcomes 5 4 3 2 1 Please rate the faculty on their knowledge, expertise, and teaching ability (5= excellent, 3 = good, 1 = poor). Deepak Bhatt, MD, MPH, FACC, FAHA, FESC, MSCAI 5 4 3 2 1 Chuck Vega, MD 5 4 3 2 1 Please rate the following components relating to this activity: Content 5 4 3 2 1 Relevance to your practice 5 4 3 2 1 Educational format 5 4 3 2 1 Audience-participation portions (eg., Q&A, polling, pre/post-testing) 5 4 3 2 1 Resources and/or other materials supporting the activity 5 4 3 2 1 Overall 5 4 3 2 1 Therapeutic recommendations presented in this activity did not encourage inappropriate or excessive use of products/devices. Agree Disagree How many patients with CVD do you see during a typical month? 0 patients 1-10 patients 11-20 patients 21-30 patients More than 30 patients Do you feel like there were any new data presented? Yes, please specify: No Did you learn anything new? Yes, please specify: No Did you gain confidence on the new information? Yes, why? No, why? Did this program include opportunities to learn as a part of a healthcare team? Yes, please specify: No Cardiovascular disease is the leading cause of death for men and women in the United States, representing 1 in every _____ deaths. 3 4 5 6 Which of the following has shown the most promise in mitigating CVD risk? EPA + DHA EPA only Fibrates Niacin Which of the following agents is the first EPA-only prescription product and the first FDA-approved medication to reduce cardiovascular risk beyond cholesterol-lowering therapy in high-risk adults? Atorvastatin Bezafibrate Icosapent ethyl Pemafibrate How confident are you now in your ability to implement recent data, newer therapeutic strategies, and guideline-directed care in clinical practice to minimize CVD risk and improve patient outcomes? Very confident Confident Somewhat confident Not very confident Not at all confident Do you intend to make any additional changes to your practice as a result of information gained from this activity? Please be specific. Yes, please describe: No What challenges or barriers outside of your control may prevent you from changing your practice? Adverse effects of available treatments Affordability/cost Institutional policy Insurance/formulary Lack of patient education/engagement Limited resources/time Need more information on optimal management strategies Outdated or unclear guidelines Patient adherence Other: How might future activities help you address those barriers? 255 characters max The information presented in this activity did not serve to advance a proprietary interest of any commercial entity. Agree Disagree Based on my participation in this activity, I anticipate I will more often (select all that apply): Adhere to the most current guidelines and recommendations for CVD risk management Assess for signs, symptoms, and laboratory findings of CVD in at-risk patients Incorporate appropriate strategies, including patient education and improved communication, into practice to promote healthy lifestyle practices and minimize CVD risk Remain apprised of promising clinical trial data as well as approvals and newer indications granted by the FDA to minimize CVD risk Implement newer therapeutic strategies into routine care to minimize CVD risk Utilize omega-3 fatty acids, particularly EPA, in appropriate patients to minimize the rate of CVD events Other, please specify: Previous
